Herantis Pharma has announced the initiation of a 'non-invasive' CDNF (cerebral dopamine neurotrophic factor) development programme to broaden the application of CDNF in treating Parkinson's.

Naturally present in the human blood circulation and cerebrospinal fluid, CDNF is a potent neuroprotective factor that promotes neuronal survival. In preclinical proof-of-concept studies CDNF has demonstrated beneficial effects in Parkinson's alleviating both motor and non-motor symptoms and stopping disease progression. 

Herantis is currently evaluating natural CDNF in a Phase 1-2 clinical study at three European university hospitals. In this study, CDNF is injected directly into the brain using a specialised delivery system. Building on Herantis' drug development expertise, the company is also now planning development of a non-invasive CDNF programme to translate the new discoveries into clinical studies.

Pekka Simula, Herantis' CEO, said "Based on broad and robust preclinical data, we believe CDNF can make a significant difference in the treatment of Parkinson's disease and we look forward to exploring the new possibilities a non-invasive administration could offer to provide the best product for the benefit of patients."

Read the full article in 'Parkinson's News Today' : herantis-starts-developing-non-invasive-cdnf-parkinsons-treatment/